Abstract:BACKGROUND:Glycogen synthase kinase-3 (GSK-3) plays an important role in human cancer. The aim of this study is to evaluate the clinicopathological significance of expression of GSK-3α/β and pGSK-3α/β(Tyr279/216) in patients with epithelial ovarian cancer and to investigate whether GSK-3 inhibition can influence cell viability and tumor growth of ovarian cancer. METHODS:Immunohistochemistry was used to examine expression of GSK-3α/β and pGSK-3α/β(Tyr279/216) in 71 human epithelial ovarian cancer tissues and correlations between protein expression, and clinicopathological factors were analyzed. Cell viability was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay following exposure of ovarian carcinoma cells to pharmacological inhibitors of GSK-3 or GSK-3 small interfering RNA. In vivo validation of tumor growth inhibition was performed with xenograft mice. RESULTS:The expression levels of GSK-3α/β and pGSK-3α/β(Tyr279/216) in ovarian cancers were significantly higher than those in benign tumors. High expression of GSK-3α/β was more likely to be found in patients with advanced International Federation of Gynecology and Obstetrics (FIGO) stages and high serum cancer antigen 125. Higher expression of pGSK-3α/β(Tyr279/216) was associated with advanced FIGO stages, residual tumor mass, high serum cancer antigen 125, and poor chemoresponse. Worse overall survival was revealed by Kaplan-Meier survival curves in patients with high expression of GSK-3α/β or pGSK-3α/β(Tyr279/216). Multivariate analysis indicated that FIGO stage, GSK-3α/β expression, and pGSK-3α/β(Tyr279/216) expression were independent prognostic factors for overall survival. GSK-3 inhibition by lithium chloride, 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione (TDZD-8), or GSK-3 small interfering RNA can decrease viability of SKOV3 and SKOV3-TR30 ovarian cancer cells. Additionally, lithium chloride-treated SKOV3 xenograft mice had a significant reduction in tumor growth compared with control-treated animals. CONCLUSION:Our findings suggest that overexpression and aberrant activation of GSK-3 may contribute to progression and poor prognosis in ovarian cancer. Inhibition of GSK-3 may be a potential therapy for ovarian cancer.

The Discovery of Novel Benzothiazinones As Highly Selective Non-Atp Competitive Glycogen Synthase Kinase 3β Inhibitors for the Treatment of Ovarian Cancer

Clinicopathological and biological significance of aberrant activation of glycogen synthase kinase-3 in ovarian cancer.

Design, Biological Characterization, and Discovery of Novel Cyclohexenyl Derivatives as Kinesin KIF18A Inhibitors for the Treatment of Ovarian Cancer

A quinoline-2-thione derivative as a novel chemotherapy drug candidate displays anti-tumor activity in vitro and in vivo

Novel 2-Phenyl-3-(pyridin-2-yl) Thiazolidin-4-one Derivatives As Potent Inhibitors for Proliferation of Osteosarcoma Cells in Vitro and in Vivo

Investigating Isoquinoline Derivatives for Inhibition of Inhibitor of Apoptosis Proteins for Ovarian Cancer Treatment.

Ginkgetin suppresses ovarian cancer growth through inhibition of JAK2/STAT3 and MAPKs signaling pathways

Thieno[2,3-b]pyridine's Impact on Glycosphingolipid Expression, Cytotoxicity, Apoptosis, and Metabolomics in Ovarian Tumor Cell Lines

Design, Synthesis and in Vitro Tumor Cytotoxicity Evaluation of 3,5‐diamino‐n‐substituted Benzamide Derivatives As Novel GSK‐3β Small Molecule Inhibitors

Structure-based virtual screening identified novel FOXM1 inhibitors as the lead compounds for ovarian cancer

Discovery of Novel Phosphoinositide-3-Kinase α Inhibitors with High Selectivity, Excellent Bioavailability, and Long-Acting Efficacy for Gastric Cancer

Glycogen synthase kinase-3β inhibitors as a novel promising target in the treatment of cancer: Medicinal Chemistry Perspective

Discovery of a Novel Covalent EZH2 Inhibitor Based on Tazemetostat Scaffold for the Treatment of Ovarian Cancer.

Preclinical efficacy of CBR-5884 against epithelial ovarian cancer cells by targeting the serine synthesis pathway

Discovery of 2-(Anilino)pyrimidine-4-carboxamides as Highly Potent, Selective, and Orally Active Glycogen Synthase Kinase-3 (GSK-3) Inhibitors

Design,synthesis and biological evaluation of benzothiazinones as novel non-ATP competitive inhibitors of glycogen synthesis kinase 3β(GSK-3β)

Discovery of tertiary amide derivatives incorporating benzothiazole moiety as anti-gastric cancer agents in vitro via inhibiting tubulin polymerization and activating the Hippo signaling pathway

Discovery of Novel Benzothiazepinones as Irreversible Covalent Glycogen Synthase Kinase 3 Inhibitors for the Treatment of Acute Promyelocytic Leukemia

Optical Coherence Tomography of Tumor Spheroids Identifies Candidates for Drug Repurposing in Ovarian Cancer

Design, synthesis and biological evaluation of a series of novel pyrrolo[2,3-d]pyrimidin/pyrazolo[3,4-d]pyrimidin-4-amine derivatives as FGFRs-dominant multi-target receptor tyrosine kinase inhibitors for the treatment of gastric cancer

Discovery of a novel dual-target inhibitor against RSK1 and MSK2 to suppress growth of human colon cancer